Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 6/20 | 0.44 |
| ▸ | IDO1 | P14902 | 3/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.32 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7299082 | 0.87 | ABCC9 (0.36) | ABCC9IDO1TRPV1 | |
| SCHEMBL7253544 | 0.77 | IDO1 (0.44) | IDO1HTR2BGAAL3MBTL1 | |
| SCHEMBL13380562 | 0.77 | IDO1 (0.44) | IDO1HTR2BGAAL3MBTL1 | |
| SCHEMBL7292872 | 0.72 | ABCC9 (0.46) | ABCC9IDO1CCNCCDK8HASPIN | |
| SCHEMBL9042201 | 0.72 | ABCC9 (0.49) | ABCC9CCNCCDK8HASPINCDK19 | |
| SCHEMBL9042189 | 0.72 | ABCC9 (0.49) | ABCC9CCNCCDK8HASPINCDK19 | |
| SCHEMBL9832783 | 0.72 | ABCC9 (0.46) | ABCC9IDO1CCNCCDK8HASPIN | |
| SCHEMBL7292871 | 0.72 | ABCC9 (0.46) | ABCC9IDO1CCNCCDK8HASPIN | |
| SCHEMBL9042195 | 0.72 | ABCC9 (0.49) | ABCC9CCNCCDK8HASPINCDK19 | |
| SCHEMBL5868353 | 0.71 | IDO1 (0.40) | IDO1HTR2BGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0205292-B1 | Pyrano[3,2-c]pyridine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1991-11-06 | — | — | EP | claimed |
| US-4904784-A | Active compounds | BEECHAM GROUP P.L.C. (GB) | 1990-02-27 | — | — | US | claimed |
| EP-0205292-A2 | Pyrano[3,2-c]pyridine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1986-12-17 | — | — | EP | claimed |
| EP-1937669-B9 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-18 | — | — | EP | disclosed |
| EP-1937669-B1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | disclosed |
| US-7838553-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-23 | — | — | US | disclosed |
| US-7812183-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-12 | — | — | US | disclosed |
| EP-1940516-A2 | BENZOPYRAN AND PYRANOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | Janssen Pharmaceutica, N.V. (BE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1937669-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | disclosed |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-29 | — | — | US | disclosed |
| WO-2007027780-A2 | BENZOPYRAN AND PYRANOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | WO | disclosed |
| US-5418232-A | Hypotensive, increases renal blood flow | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1995-05-23 | — | — | US | disclosed |
| US-5254557-A | Administering for reversible airways obstruction and asthma | BEECHAM GROUP P.L.C. (GB) | 1993-10-19 | — | — | US | disclosed |
| EP-0308792-B1 | AZACHROMANE DERIVATIVES | MERCK PATENT GmbH (DE) | 1993-07-28 | — | — | EP | disclosed |
| WO-1990014346-A1 | BENZOPYRAN DERIVATIVES | BEECHAM GROUP PLC (GB) | 1990-11-29 | — | — | WO | disclosed |
| EP-0398665-A1 | Benzopyran derivatives | Beecham Group p.l.c. (GB) | 1990-11-22 | — | — | EP | disclosed |
| EP-0373204-A1 | NOVEL COMPOUNDS AND TREATMENT | BEECHAM GROUP PLC (GB) | 1990-06-20 | — | — | EP | disclosed |
| US-4931454-A | Azachroman derivatives with effects on the cardiovascular system | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-06-05 | — | — | US | disclosed |
| WO-1989010925-A1 | NOVEL COMPOUNDS AND TREATMENT | BEECHAM GROUP PLC (GB) | 1989-11-16 | — | — | WO | disclosed |
| EP-0308792-A2 | Azachromane derivatives | MERCK PATENT GmbH (DE) | 1989-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | ABCC9 217/4885IDO1 4077/4885TRPV1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.